This short presentation by Jaheed Khan was given on 12th April 2016 as part of a series of talks at Clinica London given to a group of optometrists and general practitioners.

1. AMD – a glimpse into the future
Jaheed Khan

3. Symptoms of AMD

4. Dry AMD

5. Wet AMD

6. Wet AMD scarring

8. Dry AMD OCT

9. OCT wet AMD

10. Treatments for Dry AMD
No medical treatment for dry type
Magnifying vision and good illumination help

11. IMT for end stage AMD

12. Focal laser for wet AMD

13. Photodynamic therapy

14. RPE Cell Translocation

15. VEGF

16. Anti –VEGF Rx

17. Anti-VEGF differences

18. Radiotherapy Rx for wet AMD

19. Future AMD Rx

20. Future AMD Rx

21. Future AMD Rx

22. Future AMD Rx

23. Future AMD Rx

24. Future AMD Rx

25. Future AMD Rx
Dry AMD pipeline: most promising candidates
• Ciliary Neurotrophic Factor: Neuroprotective implant, phase II
• Fenretinide: Decreases serum retinol, oral, phase II
• OT-551: Anti-oxidant, anti inflammatory, topical, phase II
• POT-4: Complement C3 inhibitor, phase II
• Glatiramer Acetate: Immunomodulator, subcutaneous, phase II
• Rheopheresis: Plasmapheresis, phase III

26. Future AMD Rx
Wet AMD pipeline: most promising candidates
• adPEDF.11: Gene therapy, intravitreal injection, phase I
• AGN211745: siRNA, intravitreal injection, phase II
• Zybrestat: vascular disrupting agent, topical, animal studies
• Sirolimus: Multi-mechanism, Subconjunctival or intravitreal injection or oral, phase
II
• ATG003: nAChR antagonist, topical , phase II
• Vatalanib: Tyrosine kinase inhibitor, oral, phase II
• Pazopanib: Tyrosine kinase inhibitor, , topical , phase II
• TG101095 / TG100801: Tyrosine kinase inhibitor, topical, phase II
• AL-39324: Tyrosine kinase inhibitor, intravitreal injection, animal studies
• AG013958: Tyrosine kinase inhibitor, subtenon injection, animal studies
• JSM6427: integrin antagonist, intravitreal injection, phase I
• PF-04523655 (REDD14NP) Wet AMD; phase I (Quark/Pfizer)

27. AMD – a glimpse into the future